Total Voting Rights
3 January 2017 16:00
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 December 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,229,424 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,229,424.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Enquiries | ||
Neil Burrows | UK/Global | +44 203 749 5637 |
Vanessa Rhodes | UK/Global | +44 203 749 5736 |
Karen Birmingham | UK/Global | +44 203 749 5634 |
Rob Skelding | UK/Global | +44 203 749 5821 |
Jacob Lund | Sweden | +46 8 553 260 20 |
Michele Meixell | US | +1 302 885 2677 |
Investor Relations | ||
Thomas Kudsk Larsen | +44 203 749 5712 | |
Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
Henry Wheeler | Oncology | +44 203 749 5797 |
Mitchell Chan | Oncology | +1 240 477 3771 |
Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
Nick Stone | Respiratory | +44 203 749 5716 |
Christer Gruvris | Autoimmunity, neuroscience & infection | +44 203 749 5711 |
US toll free | +1 866 381 7277 |
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-